Previous Article | Next Article 
Journal of Virology, March 2006, p. 2855-2862, Vol. 80, No. 6
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.6.2855-2862.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Cyclophilin A and TRIM5
Independently Regulate Human Immunodeficiency Virus Type 1 Infectivity in Human Cells
Elena Sokolskaja,1
Lionel Berthoux,1 and
Jeremy Luban1,2*
Departments of Microbiology,1
Medicine, Columbia University, New York, New York2
Received 23 March 2005/
Accepted 7 December 2005
Cyclophilin A (CypA), a cytoplasmic, human immunodeficiency virus type 1 (HIV-1) CA-binding protein, acts after virion membrane fusion with human cells to increase HIV-1 infectivity. HIV-1 CA is similarly greeted by CypA soon after entry into rhesus macaque or African green monkey cells, where, paradoxically, the interaction decreases HIV-1 infectivity by facilitating TRIM5
-mediated restriction. These observations conjure a model in which CA recognition by the human TRIM5
orthologue is precluded by CypA. Consistent with the model, selection of a human cell line for decreased restriction of the TRIM5
-sensitive, N-tropic murine leukemia virus (N-MLV) rendered HIV-1 transduction of these cells independent of CypA. Additionally, HIV-1 virus-like particles (VLPs) saturate N-MLV restriction activity, particularly when the CA-CypA interaction is disrupted. Here the effects of CypA and TRIM5
on HIV-1 restriction were examined directly. RNA interference was used to show that endogenous human TRIM5
does indeed restrict HIV-1, but the magnitude of this antiviral activity was not altered by disruption of the CA-CypA interaction or by elimination of CypA protein. Conversely, the stimulatory effect of CypA on HIV-1 infectivity was completely independent of human TRIM5
. Together with previous reports, these data suggest that CypA protects HIV-1 from an unknown antiviral activity in human cells. Additionally, target cell permissivity increased after loading with heterologous VLPs, consistent with a common saturable target that is epistatic to both TRIM5
and the putative CypA-regulated restriction factor.
* Corresponding author. Mailing address: Department of Microbiology, Columbia University, 701 West 168th Street, New York, NY 10032. Phone: (212) 305-8710. Fax: (212) 305-0333. E-mail:
jl45{at}columbia.edu.
Journal of Virology, March 2006, p. 2855-2862, Vol. 80, No. 6
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.6.2855-2862.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Hanoulle, X., Badillo, A., Wieruszeski, J.-M., Verdegem, D., Landrieu, I., Bartenschlager, R., Penin, F., Lippens, G.
(2009). Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B. J. Biol. Chem.
284: 13589-13601
[Abstract]
[Full Text]
-
Sebastian, S., Grutter, C., de Castillia, C. S., Pertel, T., Olivari, S., Grutter, M. G., Luban, J.
(2009). An Invariant Surface Patch on the TRIM5{alpha} PRYSPRY Domain Is Required for Retroviral Restriction but Dispensable for Capsid Binding. J. Virol.
83: 3365-3373
[Abstract]
[Full Text]
-
Ylinen, L. M. J., Schaller, T., Price, A., Fletcher, A. J., Noursadeghi, M., James, L. C., Towers, G. J.
(2009). Cyclophilin A Levels Dictate Infection Efficiency of Human Immunodeficiency Virus Type 1 Capsid Escape Mutants A92E and G94D. J. Virol.
83: 2044-2047
[Abstract]
[Full Text]
-
Parrish, C. R., Holmes, E. C., Morens, D. M., Park, E.-C., Burke, D. S., Calisher, C. H., Laughlin, C. A., Saif, L. J., Daszak, P.
(2008). Cross-Species Virus Transmission and the Emergence of New Epidemic Diseases. Microbiol. Mol. Biol. Rev.
72: 457-470
[Abstract]
[Full Text]
-
Ptak, R. G., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., de Bethune, M.-P., Neyts, J., De Clercq, E., Dumont, J.-M., Scalfaro, P., Besseghir, K., Wenger, R. M., Rosenwirth, B.
(2008). Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrob. Agents Chemother.
52: 1302-1317
[Abstract]
[Full Text]
-
Warrilow, D., Meredith, L., Davis, A., Burrell, C., Li, P., Harrich, D.
(2008). Cell Factors Stimulate Human Immunodeficiency Virus Type 1 Reverse Transcription In Vitro. J. Virol.
82: 1425-1437
[Abstract]
[Full Text]
-
Gourlay, L. J., Angelucci, F., Baiocco, P., Boumis, G., Brunori, M., Bellelli, A., Miele, A. E.
(2007). The Three-dimensional Structure of Two Redox States of Cyclophilin A from Schistosoma mansoni: EVIDENCE FOR REDOX REGULATION OF PEPTIDYL-PROLYL CIS-TRANS ISOMERASE ACTIVITY. J. Biol. Chem.
282: 24851-24857
[Abstract]
[Full Text]
-
Takeuchi, H., Buckler-White, A., Goila-Gaur, R., Miyagi, E., Khan, M. A., Opi, S., Kao, S., Sokolskaja, E., Pertel, T., Luban, J., Strebel, K.
(2007). Vif Counteracts a Cyclophilin A-Imposed Inhibition of Simian Immunodeficiency Viruses in Human Cells. J. Virol.
81: 8080-8090
[Abstract]
[Full Text]
-
Yang, R., Aiken, C.
(2007). A Mutation in Alpha Helix 3 of CA Renders Human Immunodeficiency Virus Type 1 Cyclosporin A Resistant and Dependent: Rescue by a Second-Site Substitution in a Distal Region of CA. J. Virol.
81: 3749-3756
[Abstract]
[Full Text]
-
Luban, J.
(2007). Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection. J. Virol.
81: 1054-1061
[Full Text]
-
Saini, M., Potash, M. J.
(2006). Novel Activities of Cyclophilin A and Cyclosporin A during HIV-1 Infection of Primary Lymphocytes and Macrophages. J. Immunol.
177: 443-449
[Abstract]
[Full Text]